|Bid||1.9400 x 3200|
|Ask||1.9500 x 3000|
|Day's Range||1.8350 - 1.9550|
|52 Week Range||1.6800 - 3.8400|
|Beta (5Y Monthly)||0.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GERN
FOSTER CITY, Calif., December 04, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will be available in print at a later date.
FOSTER CITY, Calif., November 28, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board leve
FOSTER CITY, Calif., November 16, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.